Inspire Medical Systems, Inc. (NYSE:INSP) CTO John Rondoni Sells 58 Shares

Inspire Medical Systems, Inc. (NYSE:INSP) CTO John Rondoni sold 58 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $215.00, for a total value of $12,470.00. Following the sale, the chief technology officer now directly owns 11,322 shares in the company, valued at approximately $2,434,230. This represents a 0.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Inspire Medical Systems Price Performance

NYSE INSP opened at $203.03 on Friday. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $257.40. The firm has a market capitalization of $6.08 billion, a PE ratio of 189.75 and a beta of 1.32. The company’s 50 day simple moving average is $191.71 and its 200 day simple moving average is $183.39.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.54. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. The company had revenue of $203.20 million for the quarter, compared to the consensus estimate of $197.59 million. During the same quarter in the previous year, the business earned ($0.29) EPS. The company’s quarterly revenue was up 32.6% compared to the same quarter last year. Sell-side analysts anticipate that Inspire Medical Systems, Inc. will post 1.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on INSP shares. Bank of America raised shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and lifted their price target for the company from $220.00 to $255.00 in a report on Wednesday, November 20th. Wells Fargo & Company upped their price objective on Inspire Medical Systems from $187.00 to $198.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Piper Sandler reiterated an “overweight” rating and issued a $260.00 target price (up from $255.00) on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Stifel Nicolaus restated a “hold” rating and set a $200.00 price target (up previously from $170.00) on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. Finally, Robert W. Baird lifted their price objective on shares of Inspire Medical Systems from $240.00 to $252.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $233.58.

Institutional Trading of Inspire Medical Systems

Large investors have recently added to or reduced their stakes in the business. State Street Corp lifted its position in shares of Inspire Medical Systems by 78.0% during the 3rd quarter. State Street Corp now owns 1,049,784 shares of the company’s stock valued at $221,557,000 after acquiring an additional 459,990 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Inspire Medical Systems by 954.4% during the third quarter. Point72 Asset Management L.P. now owns 319,364 shares of the company’s stock worth $67,402,000 after purchasing an additional 289,075 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Inspire Medical Systems by 798.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 267,852 shares of the company’s stock worth $56,530,000 after purchasing an additional 238,034 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Inspire Medical Systems by 152.7% during the second quarter. AQR Capital Management LLC now owns 231,845 shares of the company’s stock valued at $31,028,000 after purchasing an additional 140,090 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Inspire Medical Systems by 3,812.6% in the 3rd quarter. Principal Financial Group Inc. now owns 141,089 shares of the company’s stock valued at $29,777,000 after purchasing an additional 137,483 shares during the period. 94.91% of the stock is currently owned by institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.